Track Passage Bio, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Passage Bio, Inc. PASG · Stock Open Passage Bio, Inc. in new tab

4.25 USD
EPS
-10.35
P/B
240.31
ROE
-212.27
Beta
1.49
Target Price
15.50 USD
Loading chart...
Key Metrics
Earnings dateMarch 8, 2027
EPS-10.35
Book Value0.02
Price to Book240.31
Debt/Equity48.97
% Insiders7.711%
Estimates
Forward P/E-0.33
Forward EPS-11.55
Target Mean Price15.50

DCF valuation

Model fair value for Passage Bio, Inc. (PASG)
Result
Sign in to run the valuation for PASG.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
2 analysts · consensus Buy · mean target 15.50 USD (low 8.00, high 23.00) · as of 12 Nov 2026
Low 8.00
Mean 15.50
High 23.00
Price 4.25
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Passage Bio, Inc. Logo Passage Bio, Inc. Analysis (PASG)

United States Health Care Official Website Stock

Is Passage Bio, Inc. a good investment? Passage Bio, Inc. (PASG) is currently trading at 4.25 USD. Market analysts have a consensus price target of 15.50 USD. This suggests a potential upside from current levels.

Earnings Schedule: Passage Bio, Inc. is expected to release its next earnings report on March 8, 2027. The market consensus estimate for Forward EPS is -11.55.

Investor FAQ

Does Passage Bio, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Passage Bio, Inc.?

Passage Bio, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 8, 2027. The company currently has a trailing EPS of -10.35.

Company Profile

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.

Exchange Ticker
NMS (United States) PASG
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
July 14, 2025 1:20
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion